Clinical Trial Update: A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial compares venetoclax plus azacitidine versus azacitidine alone in treatment-naïve AML patients ineligible for standard induction therapy; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Acute Myeloid Leukemia (AML) | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-01-27